SAN DIEGO - Artiva Biotherapeutics (NASDAQ:ARTV) presented clinical data for its AlloNK therapy combined with rituximab at the European Alliance of Associations for Rheumatology Congress in London, according to a press release statement issued today.
The company reported results from 31 patients with rheumatologic diseases treated with the combination therapy. In a company-sponsored Phase 2a basket trial, 71% of rheumatoid arthritis patients with six months of follow-up achieved an ACR50 response, a measure of disease improvement.The positive clinical data comes as Artiva’s stock has delivered strong returns, with shares up 226% over the past year and 122% in the last six months, giving the company a market capitalization of $333 million. According to InvestingPro analysis, the company holds more cash than debt on its balance sheet, providing financial runway for its clinical development programs.
The pooled rheumatoid arthritis dataset included 21 patients with at least 12 weeks of follow-up. Among patients with six months of follow-up, five of six patients in an investigator-initiated trial achieved an ACR50 or modified ACR50 response, and five of seven patients in the company-sponsored trial achieved an ACR50 response. As of the April 3, 2026 data cutoff, no patient had loss of response or required additional treatments.
Artiva also presented data on patients with Sjögren disease and systemic sclerosis. In Sjögren disease patients, mean stimulated salivary flow increased from 0.65 mL/min at baseline to 1.23 mL/min at six months. In systemic sclerosis, mean modified Rodnan skin score improved by 9.5 points among patients with six months of follow-up.
Safety data from 55 autoimmune patients showed no cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, AlloNK-related serious adverse events or treatment discontinuations due to adverse events as of the data cutoff. The rate of Grade 3 or higher infections was 2%.Despite the promising clinical progress, InvestingPro data indicates the company is quickly burning through cash—typical for biotech firms in late-stage development. Analysts remain optimistic, with price targets ranging from $23 to $41, suggesting significant upside potential. The company maintains a strong current ratio of 8.16, indicating solid short-term financial health. InvestingPro subscribers have access to 10 additional exclusive tips and comprehensive financial metrics for ARTV.
The U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to AlloNK plus rituximab for refractory rheumatoid arthritis. The designation provides access to expedited development and review benefits.
AlloNK is an allogeneic, off-the-shelf, non-genetically modified natural killer cell therapy candidate being evaluated in combination with anti-CD20 monoclonal antibodies. Artiva plans to initiate a Phase 3 registrational trial in refractory rheumatoid arthritis in 2026.
In other recent news, Artiva Biotherapeutics announced significant developments in its ongoing research and corporate structure. The company is set to present clinical data on its AlloNK therapy at the European Alliance of Associations for Rheumatology Congress, highlighting that 71% of refractory rheumatoid arthritis patients achieved an ACR50 response after six months of follow-up. Additionally, Artiva has made notable executive changes, appointing Diego Miralles, M.D., as President and Head of Research and Development, following his resignation from the board of directors. Dr. Miralles brings extensive experience from his previous roles at Laronde Inc., Vividion Therapeutics, and Johnson & Johnson.
Cantor Fitzgerald reiterated an Overweight rating for Artiva Biotherapeutics, maintaining a $40.00 price target, while H.C. Wainwright raised its price target to $35 from $15, maintaining a Buy rating. These updates come after Artiva revealed initial results from its Phase 2a basket trial in B-cell autoimmune diseases, with a focus on rheumatoid arthritis. The data showed promising results with 21 patients having at least 12 weeks of follow-up and 13 patients with six months or more of follow-up. These developments indicate ongoing progress in Artiva’s strategic and research efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates ARTV alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if ARTV is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?